o extend its presence in Germany, one of Europes largest markets, Latvian pharmaceutical company Kalceks JSC has struck a long-term distribution deal with EVER Pharma. EVER Pharma, which is headquartered in Austria, has a strong commercial presence in Germany and internationally, informs Kaspars Kuprevičs, Member of the Board at Kalceks.
The cooperation with EVER Pharma covers five products and will nearly double the number of Kalceks products currently marketed in Germany. The products cover multiple therapeutic areas including cardiology, central nervous system, and oncology supportive care.
"In the last years, the hospital product segment, in which Kalceks and EVER Pharma operate, has seen rapid growth all over Europe. Kalceks has been represented on the German market since 2019, and now is the right moment to strengthen our positions and extend our product portfolio. We are pleased to partner with an experienced and reputable company leading the hospital product segment. We see a great synergy between our German portfolio and EVER Pharma products," explains Kaspars Kuprevičs, Member of the Board at Kalceks.
Penetration of export markets and new product launches are the cornerstones of Kalceks development strategy. Over the past years, it has produced good operational results and significantly increased the company's turnover, Mr. Kuprevičs emphasizes. The signed agreement with EVER Pharma will allow working toward the commercialization of other drugs produced by the Latvian company, thus reaching customers - health care institutions - sooner. Currently, there are 16 Kalceks products registered on the German market, and another eight medicines are to be registered by the end of the year.
”The strategic cooperation between Kalceks and EVER Pharma in Germany will broaden our portfolio with products manufactured in Europe and further strengthen our hospital presence ”, explains Mr. Norbert Hittenberger, Head of Commercial Operations for Europe at EVER Pharma. Further product supply from within Europe is highly appreciated by the majority of the hospital pharmacists challenged by various supply issues in the past.
The specialty medications for the hospital segment, which saw rapid growth in 2021, comprise a significant share of the Kalceks product portfolio. Last year, the highest demand was for myorelaxants and anaesthetics. In addition, in 2021, the company's range of products was supplemented with seven new generics. Forty-two medicines currently are under development. Last year, Kalceks initiated the registration procedure of nine generic medications in the European Union countries, including four sterile antibiotic products for the hospital segment.
Kalceks exports its medications to 77 countries worldwide, with 60% of its products to European countries. The key markets for the top products are Western European countries: Spain, Belgium, the UK, France, the Netherlands, and Israel in the Middle East region. Apart from Europe, medications produced by Kalceks are also available in North America, South America, Africa, and Asia.